Skip to main content

Advertisement

SpringerLink
Log in

Prostate cancer

Better VISTAs ahead? Potential and pitfalls of immunotherapy

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Despite a rapid increase in the use of anticancer immunotherapy, our understanding of the mechanisms of action and the patients' responses remains limited. The discovery of immune inhibitory markers in the tumour microenvironment following immunotherapy should improve our understanding and might enable us to better apply combination therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551–555 (2017).

    Article  CAS  Google Scholar 

  2. Fong, L. et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl Cancer Inst. 106, dju268 (2014).

    Article  Google Scholar 

  3. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

    Article  CAS  Google Scholar 

  4. Beer, T. M. et al. Randomized, double-blind, Phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017).

    Article  CAS  Google Scholar 

  5. Graff, J. N. et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7, 52810–52817 (2016).

    PubMed  PubMed Central  Google Scholar 

  6. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).

    Article  CAS  Google Scholar 

  7. Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).

    Article  CAS  Google Scholar 

  8. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

    Article  Google Scholar 

  9. Nowak, E. C. et al. Immunoregulatory functions of VISTA. Immunol. Rev. 276, 66–79 (2017).

    Article  CAS  Google Scholar 

  10. Dhodapkar, K. M. et al. Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases [abstract]. J. Clin. Oncol. 35 (suppl 7S), 3 (2017).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ravi A. Madan and James L. Gulley are at the Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive 13N240, Bethesda, Maryland 20892, USA.,

    Ravi A. Madan & James L. Gulley

Authors
  1. Ravi A. Madan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James L. Gulley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James L. Gulley.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Madan, R., Gulley, J. Better VISTAs ahead? Potential and pitfalls of immunotherapy. Nat Rev Urol 14, 455–456 (2017). https://doi.org/10.1038/nrurol.2017.75

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2017.75

  • Springer Nature Limited

This article is cited by

Search

Navigation